Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA Haploidentical Transplant with Post-Transplant Cyclophosphamide

Graft-versus-host disease (GVHD) is a major complication of allogeneic blood or marrow transplantation (BMT). Grades II to IV acute (a)GVHD occurs in 40% to 60% [1] and chronic (c)GVHD in 30% to 70% [2,3] of patients receiving HLA-matched sibling donor BMT using calcineurin inhibitor –based GVHD prophylaxis. aGVHD and cGVHD are leading causes of nonrelapse mortality (NRM) [4-9], but they also reduce quality of life as a result of end-organ damage and adverse effects related to immunosuppressive therapy [9-13].

Source: Biology of Blood and Marrow Transplantation - October 18, 2017 Category: Hematology Authors: Shannon R. McCurdy, Christopher G. Kanakry, Hua-Ling Tsai, Yvette L. Kasamon, Margaret M. Showel, Javier Bola ños-Meade, Carol Ann Huff, Ivan Borrello, William H. Matsui, Robert A. Brodsky, Richard F. Ambinder, Maria P. Bettinotti, Ephraim J. Fuchs, Gary Source Type: research